1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Shanghai Pharmaceuticals Holding Co. Ltd. Class A

Shanghai Pharmaceuticals Holding Co. Ltd. Class A

1.20
EUR
0.00
(0.00%)
7.77BMarket Cap
Oct 29Next Earn
Shanghai Pharmaceuticals Holding Co. Ltd. Class A
STU:S1R
(Stuttgart Stock Exchange)

Recent

price

1.20

P/E

ratio

- -

div

yld

3.48%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
11.32
13.21
14.75
16.94
20.01
22.85
26.16
28.34
32.7
38.34
39.28
44.17
38.72
41.04
43.31
44.43
- -
Revenue per Share
0.43
0.49
0.44
0.48
0.56
0.62
0.69
0.76
0.8
0.84
0.92
1.04
0.94
0.59
0.72
0.9
- -
Basic EPS, GAAP
0.48
0.33
0.1
0.01
0.01
-0.08
-0.04
0.14
0.25
0.67
0.78
0.19
0.34
0.36
0.54
0.6
- -
Free Cash Flow per Basic Share
0.17
0.19
0.19
0.23
0.27
0.3
0.31
0.38
0.48
0.53
0.49
0.55
0.52
0.63
0.57
0.44
0.32
Dividend per Share
2.93
5
5.34
5.62
6.03
6.48
6.85
7.37
7.99
8.54
9.29
10.11
10.56
10.78
11.26
11.92
12.3
Book Value per Share
2.54
4.07
4.34
4.5
4.65
5.01
4.98
5.35
4.79
5.48
5.86
6.52
7.74
7.98
8.59
8.54
8.97
Tangible Book Value per Share
3,421
4,156
4,617
4,617
4,617
4,617
4,617
4,617
4,864
4,866
4,886
4,886
5,991
6,343
6,355
6,383
4,383
Basic Weighted Avg Shares
38,722
54,900
68,078
78,223
92,399
105,517
120,765
130,847
159,084
186,566
191,909
215,824
231,981
260,295
275,251
283,580
- -
Sales/Revenue/Turnover
5.24
4.43
3.92
3.71
3.67
3.75
3.53
3.8
3.92
4.25
4.24
3.67
3.79
3.67
3.52
3.27
- -
Operating Margin (%)
398
479
537
550
585
673
746
840
1,169
1,885
2,138
2,140
2,222
2,187
2,419
2,862
- -
Depreciation Expense
1,456
2,042
2,053
2,214
2,591
2,877
3,196
3,521
3,881
4,081
4,496
5,093
5,617
3,768
4,553
5,725
- -
Net Income, GAAP
18.21
19.41
20.31
19.48
21.26
19.36
17.45
22.04
16.6
22.86
21.88
22.95
20.62
26.76
26.81
28.98
- -
Effective Tax Rate (%)
3.76
3.72
3.02
2.83
2.8
2.73
2.65
2.69
2.44
2.19
2.34
2.36
2.42
1.45
1.65
2.02
- -
Profit Margin (%)
5,072
15,140
16,704
16,812
16,656
16,159
19,154
19,010
24,568
23,484
19,430
24,670
38,822
40,062
45,785
45,266
47,960
Working Capital
66
52
41
125
105
93
2,836
2,959
9,600
10,290
2,685
8,592
7,561
7,336
9,728
5,385
4,751
LT Debt
12,828
25,981
27,701
29,001
31,099
33,808
36,834
39,676
46,433
49,386
54,741
59,066
78,002
80,326
83,742
89,787
92,786
Total Equity
11.22
9.39
7
7.31
7.01
7.15
7.78
7.75
6.49
5.9
6.48
10.06
9.31
4.66
4.65
5.19
- -
Return on Invested Capital (%)
7.6
8.05
6.28
6.39
7.14
6.89
6.59
6.93
6.4
5.44
5.27
5.73
5.39
3.09
3.55
4.13
- -
Return on Capital (%)
15.92
12.34
8.6
8.75
9.64
9.96
10.39
10.72
10.63
10.12
10.33
10.76
9.65
5.56
6.49
7.76
- -
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
46,901
48,871
48,232
LT Borrowings
4,236
3,257
3,277
LT Finance Leases
1,149
1,463
1,474
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,367
6,367
6,367
Market Capitalization
64,898
62,445
60,213

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
180,464
182,841
188,381
Cash, Cash Equivalents & STI
43,083
41,117
45,990
Accounts Receivable, Net
82,306
91,150
90,768
Inventories
45,359
41,682
42,685
Total Current Liabilities
135,198
136,509
140,422
Payables & Accruals
- -
- -
- -
ST Debt
46,901
48,871
48,232
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
10.88%
7.22%
Free Cash Flow
-13.17%
23.22%
11.73%
Net Income, GAAP
8.4%
7.44%
25.74%
Sales/Revenue/Turnover
10.54%
8.19%
3.03%
Total Cash Common Dividend
8.71%
4.63%
-22.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
70,153
69,260
70,216
65,622
275,251
2025
70,763
70,830
- -
68,507
283,580
2026
75,262
72,208
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.24
0.38
0.3
0.13
0.72
2025
0.21
0.84
- -
0.16
0.9
2026
0.22
0.56
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
0.11
0.59
0.13
0.57
2025
0.06
0.12
- -
0.11
0.44
2026
0.11
0.09
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Shanghai Pharmaceuticals Holding Co., Ltd. (601607.SS) engages in the research, development, manufacturing, distribution, and retailing of pharmaceutical and healthcare products primarily in China and internationally. The company operates through four main segments—Production, Distribution, Retail, and Others—offering a broad portfolio of chemicals and biochemicals, traditional Chinese medicines, healthcare products, and medical devices across therapeutic areas including cardiovascular, digestive tract and metabolism, systemic anti-infection, central nervous system, anti-tumor and immunomodulators, musculoskeletal, respiratory systems, immune metabolism, motor neuron disease, endocrinology, psychoneurotic, neoplasm, autoimmunity, hypertension, neuromyelitis, diabetes, Alzheimer’s, inflammatory bowel diseases, and others; it provides pharmaceutical distribution, warehousing, logistics, value-added supply chain solutions, and operates a network of retail pharmacy stores serving hospitals, distributors, and consumers. Founded in 1994 and headquartered in Shanghai, China, the company targets domestic and overseas markets with innovative drugs, chemical drugs, rare disease treatments, and services in pharmaceutical industry and business segments. Recent developments include participation as a limited partner with a RMB 1 billion investment in the Shanghai Biomedical M&A Private Equity Fund established in March 2025 alongside partners such as Xinhua Insurance and Tofflon for equity investments and asset management; agreement alongside GP Health Service Capital Co., Ltd. to acquire Shanghai Hutchison Pharmaceuticals Limited for approximately USD 608 million in early 2025; acquisition of an additional 10% stake in Shanghai Shangshi Group Finance Co., Ltd.; ongoing R&D investments reaching RMB 1.729 billion in the first nine months of 2025 with 57 new drug pipelines (including 45 innovative ones) accepted for clinical trials or in progress, such as the BCD-085 anti-interleukin-17 project; and a share buyback program with an adjusted price ceiling of RMB 20.73 per share.